



30 October 2020

Company Announcements Office
ASX Limited
(via ASX Online)

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

dorsaVi Ltd (dorsaVi or the Company) has today issued 57,856,881 shares under a placement (which was announced to ASX on 22 October 2020).

The Company gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**) in compliance with the requirements of section 708A(6) that:

- (a) the shares were issued without disclosure to investors under part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, the Company has complied with:
 - (1) the provisions of chapter 2M of the Corporations Act as they apply to the Company; and
 - (2) the provisions of section 674 of the Corporations Act; and
- (c) as at the date of this notice, there is no excluded information, being information:
 - (1) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - (2) that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
 - (A) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - (B) the rights and liabilities attaching to the ordinary shares in the Company.

An Appendix 2A with respect to the above issue of shares has been lodged with the ASX.

This announcement was authorised for release by the Board of dorsaVi.

– ENDS –

For further information about dorsaVi, please contact:

dorsaVi

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
ar@dorsavi.com

dorsaVi

Matt May
General Manager
+61 409 324 949
mmay@dorsavi.com

Investor Enquiries

Ivan Lee
Vesparum Capital
+61 3 8582 4800
dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into the physical therapy (physiotherapists) market, hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance. dorsaVi's ViPerform is being used in the U.S. by the National Basketball Association (NBA), the Major League Soccer (MLS) and the National Football League (NFL). It is also used by the AFL and NRL clubs in Australia, by the English Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally. dorsaVi's Telehealth provides a virtual clinic, enabling clinicians to do business differently and take their patient consultations online.

Further information is available at www.dorsavi.com